18 October 2018 
EMA/CHMP/727925/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Kalydeco 
ivacaftor 
On 18 October 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Kalydeco. The marketing authorisation holder for this medicinal product is Vertex Pharmaceuticals (Europe) 
Ltd. 
The CHMP adopted an extension to the existing indication of Kalydeco 50 and 75 mg granules as follows:2 
“Kalydeco granules are indicated for the treatment of children with cystic fibrosis (CF) aged 2 years 
12 months and older and weighing 7 kg to less than 25 kg who have one of the following gating 
(class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, 
S549N or S549R (see sections 4.4 and 5.1).” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
                                                
